A blog bringing you perspectives from the frontlines of the drug pricing debate.

PBMs as Negotiators

Rhetoric in Washington, DC around high and rising drug prices continues to intensify. As Congress considers potential legislation,…

Partial Transparency is No Transparency at All

Although Congress has devoted much attention to exploring pharmaceutical manufacturers and pharmacy benefit managers, less attention has been…

Conservative Voices: Beware the Rush to Regulate

As Congress continues to examine the drug supply chain and how to lower prescription drug prices for Americans,…

Reason: Patient Privacy at Risk in S. 127

As Congress returns for a new work period, both parties are renewing their focus on how to bring…

Q&A: Maura Keefe and Alex Brill Discuss Understanding Drug Rebates and Their Role in Promoting Competition

Alex Brill, a senior fellow at the American Enterprise Institute and CEO of Matrix Global Advisors, recently sat…

Guest Opinion: Taking Action on the Price of Prescription Drugs: A Winning Formula

By: Ed Goeas and Brian Nienaber Read the original post on LinkedIn here. Ahead of the upcoming mid-term…

House Advances CAPD-Supported Measures to Lower Drug Prices for Patients

Americans have overwhelmingly supported action by Congress to lower Big Pharma’s drug prices for years, and now –…

Rebate Rule Elimination Will Protect Seniors from Premium Increases, Help Pay for Other Urgent Priorities

The Biden Administration should work with Congress and act now to eliminate the Rebate Rule, stop damaging Medicare…

Economist Alex Brill in Q&A With Carol Vassar on Drug Companies’ Anticompetitive Behavior

On October 1, Matrix Global Advisors’ CEO Alex Brill joined POLITICO health care contributor and podcast host Carol…

Medicare Part D Enhancements that Would Deliver Savings & Choice, Not Higher Premiums for Seniors

It’s widely agreed that Medicare Part D is one of the most successful public-private partnerships, delivering affordability and…